Irofulven has been in 19 clinical cancer trials, most studies were in prostate cancer and ovarian cancer.

Irofulven has shown a 10% response rate in patients with prostate cancer previously treated with docetaxel and 13% in ovarian cancer patients relapsing between 6 and 12 months after standard treatment with carboplatin and paclitaxel. The positive results with irofulven are not sufficient for a regulatory approval. Oncology Ventures technology (Drug Response Predictor DRP®) allows selection of the most likely responders and in May 2015 Oncology Venture in-licensed irofulven from Lantern Pharma aiming to perform focused phase 2 trails with irofulven in prostate cancer and potentially also in ovarian cancer. The irofulven project was granted 800.000 USD from Massachusetts and the Danish Swedish Medicon Valley Alliance.

irofulven  from NCI (US) Drug directory

A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens. Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle. This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents.